ClinicalTrials.gg
CompletedNCT05026320Updated Jan 22, 2025Results posted

A Clinical Trial to Compare Safety and Effectiveness for Relieving Tenderness of 10% Naproxen Gel vs. a 2.32% Diclofenac Diethylamine Gel in the Treatment of Strains and Bruises of the Legs.

A Phase 2 interventional study of Naproxen gel and Diclofenac gel in Soft Tissue Injury, sponsored by Bayer. Completed at 1 site in Germany. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Bayer · Phase 2, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Researchers are looking for a different way to treat people who have an injury to their muscles, ligaments, or tendons in their legs or feet. This is known as a "soft tissue" injury. Before a treatment is available to all patients, researchers study it in trials to better understand its safety and how well it works.

People with soft tissue injuries can have pain, swelling, and bruising.

In this trial, the researchers want to learn more about the trial treatment, BAYH006689, in participants with a soft tissue injury to their legs or feet. BAYH006689 is a naproxen gel that is used for the temporary relief of minor aches and pains of muscles and joints. The researchers will learn more about how BAYH006689 works and how safe it is in these participants.

The trial will include about 100 male and female participants between the ages of 18 and 60. All the participants will have a soft tissue injury to their legs or feet that was caused by playing sports. The injury will have happened within 3 hours of joining the trial.

The researchers will use a computer program to randomly choose what treatment each participant will receive. This will help make sure the treatments are chosen fairly and that comparing the results of the treatments is as accurate as possible. The participants will be randomly chosen to be in 1 of 3 groups:

  • Group 1: BAYH006689
  • Group 2: diclofenac diethylamine gel
  • Group 3: placebo

A placebo looks like a treatment but does not have any medicine in it. Diclofenac diethylamine gel is a treatment already available for doctors to be recommended to people with soft tissue injuries. The participants will receive their treatment once in the evening on Day 1 and then 2 times a day for 4 days. The participants will receive their final dose in the morning of Day 6. The doctors will apply the treatment to the participants' skin where the injury is.

The participants must be present at the clinic site 11 times over six days: once on Day 1 and twice daily on Days 2-6. During the trial, the doctors will:

  • check the participants' overall health and ask if they have any medical problems
  • do physical examinations to check the participants' injuries
  • use a device to see how tender and sore the participants' injuries are

In this trial, the researchers will study how tender the participants' injuries are after 3 days and at other time points over the 6 day follow-up period. They will also study how many participants have medical problems during the trial.

02

Conditions studied

  • Soft Tissue Injury

Browse trials for

03

In context

Soft Tissue Injuries

64 studies on the registry are indexed under Soft Tissue Injuries; 7 are open to participants now.

This study's enrollment of 76 is above the median of 60 across 51 interventional studies indexed under Soft Tissue Injuries.

Browse Soft Tissue Injuries studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 60 years of age inclusive, at the time of signing the .
  • Participants with a primary diagnosis of acute sports-related acute soft tissue injuries of the lower extremities that do not require hospitalization and that occurred within 3 hours of enrollment.
  • Participants with a baseline algometric measurement values on the injured site of ≤50% of the respective value at the contralateral site.
  • Participants with a baseline pain on movement (POM) of ≥50 mm on a visual analog scale (VAS) (0-100 mm).
  • Participant's absolute sensitivity to tenderness on the contralateral site is at least 2.5 N/cm2 as measured by algometry.
  • Participant's size of trauma is between 25 and 150 cm\^2.

Exclusion criteria

Exclusion Criteria:

  • Heart surgery within 2 weeks of enrollment in the study.
  • Suspected bone fracture or torn ligaments related to the injury.
  • Open wounds to the area to be treated.
  • Current skin disorders or localized infection in the area to be treated.
  • Injured area is too hairy for proper assessments.
  • Suspected head injury.
  • History of blood coagulation disorders.
  • Current or past history of gastrointestinal ulceration, gastrointestinal bleeding or other bleeding disorder(s).
  • Relevant concomitant disease such as asthma (exercise induced asthma is permitted).
  • History of significant disease deemed by the investigator to render the patient unsuitable for inclusion, including evidence or history of (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular (including hypertension and cardiac arrhythmia), hepatic, psychiatric, neurologic diseases, or within the last 5 years.
  • Participants with a medical disorder, condition, or history of such that could impair the participant's ability to participate or complete this trial in the opinion of the investigator.
  • Significant ongoing painful condition other than that associated with the sports-related injury/contusion.
  • Any ongoing condition that might interfere with the absorption, distribution, metabolism, or excretion of the study medication.
  • Females who are planning to become pregnant, are pregnant or lactating. Prior/Concomitant Therapy
  • Ice and compression are prohibited from the time of injury through the final evaluation.
  • Physical therapy or other comfort measures, or herbal preparations for bruises from the time of injury through the final evaluation.
  • Use of any medications within 5 days of enrollment until discharge from the study site (except oral , prophylactic antibiotics, synthetic thyroid hormones, methylphenidate or medications to treat benign conditions such as antibiotics to treat acne).
  • Any other treatment or medication (oral or topical), that could interfere with the trial (e.g. ) up to 3 days prior to the trial.
  • Participants with the following medical conditions may be eligible at the discretion of the investigator: ADHD on a stable dose regimen of methylphenidate/(dextro) amphetamine for at least 6 months; participants with hypothyroidism on a stable dose of synthetic thyroid hormone for at least 6 months.
  • Have received any form of treatment in the form of medication for depression in the past 6 months or any form of psychotropic agent (including selective serotonin uptake inhibitors [SSRI] but excluding ADHD medications described above) within the last 6 months.
  • Any previous history of allergy or known intolerance to naproxen, diclofenac, paracetamol or any of the drugs or formulation constituents which, in the investigator's opinion, might preclude use of an NSAID, including aspirin-sensitive asthma or a previous allergic response to a NSAID, including bronchospasm, urticaria, angioedema, and rhinitis; participation in a clinical trial in the previous 30 days.
  • Use of any over the counter (OTC) or prescription medications with which the administration of naproxen, acetaminophen, any other NSAID, is .
  • Habituation to analgesic drugs including opioids (i.e., routine use of oral analgesics 5 or more times per week for greater than 3 weeks within the past 2 years).

Other Exclusions

  • More than low-risk alcohol consumption (>24 g (males) or ˃12 g (females) of alcohol regularly per day). Amount corresponds to 0.6 L of beer/day or 0.24 L of wine/day or 3 glasses (at 2 cL) of liquor/day for males and 0.3 L of beer/day or 0.12 L of wine/day or 1 glass (at 2 cL) of liquor/day for females.
  • Self-reported drug abuse within two years prior to screening.
  • Member or first-degree relative of study staff or the Sponsor directly involved in the study.
  • Unwilling or unable to comply with all requirements outlined in the protocol.
  • Previous enrollment in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Naproxen Topical Gel (BAYH006689)

    UI Number: 1614000-268; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).

    Drug: Naproxen gel

  • Active comparator
    Diclofenac Diethylamine Gel

    UI Number: Not applicable; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).

    Drug: Diclofenac gel

  • Placebo comparator
    Placebo Gel

    UI Number: 1614000-272; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).

    Drug: Placebo gel

Interventions

  • DrugNaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    10%, bid for 5 days (final application on morning of Day 6)

  • DrugDiclofenacStudies of DiclofenacDiclofenac pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2.32% bid for 5 days (final application on morning of Day 6)

  • DrugPlacebo gel

    bid for 5 days (final application on morning of Day 6)

06

What researchers measure

Primary outcomes

  1. Tenderness (Algometry) Over the Initial 72 Hours

    Algometry area under the curve (AUC) from zero to the initial 72h post dose. The 72h AUC algometry data was an aggregate of all measurements from timepoints and data including the 72h timepoint. The average data of all participants was reported.

    Time frame: Up to the initial 72 hours post dose

Secondary outcomes

  1. Percentage of Participants With at Least One Treatment Emergent Adverse Event After Treatment

    An AE is any untoward medical occurrence in a clinical study participant, associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: After first treatment on Day 1 until follow-up visit (Day 30)

  2. Number of Participants With at Least One Treatment Emergent Adverse Event After Treatment

    An AE is any untoward medical occurrence in a clinical study participant, associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: After first treatment on Day 1 until follow-up visit (Day 30)

07

Results

Posted Jan 22, 2025

Participant flow

The study was conducted in three centers in Germany. First participant first visit of the study was on 08 AUG 2021, and last participant last visit was on 20 DEC 2021.

Participant flow — Overall Study
MilestoneNaproxen Topical GelDiclofenac Diethylamine Topical GelPlacebo
Started313015
Completed313015
Not completed000

Outcome measures

PrimaryTenderness (Algometry) Over the Initial 72 Hours

Algometry area under the curve (AUC) from zero to the initial 72h post dose. The 72h AUC algometry data was an aggregate of all measurements from timepoints and data including the 72h timepoint. The average data of all participants was reported.

Time frame:
Up to the initial 72 hours post dose
Reported as:
Mean · Nxh/cm^2
Tenderness (Algometry) Over the Initial 72 Hours
Nxh/cm^2Naproxen Topical GelDiclofenac Diethylamine Topical GelPlacebo
Tenderness (Algometry) Over the Initial 72 Hours1213.88 ± 461.111041.04 ± 274.25850.79 ± 276.04
Statistical analysis
  • Naproxen Topical Gel vs Diclofenac Diethylamine Topical Gel vs Placebo · ANCOVA · p = 0.0221
SecondaryPercentage of Participants With at Least One Treatment Emergent Adverse Event After Treatment

An AE is any untoward medical occurrence in a clinical study participant, associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
After first treatment on Day 1 until follow-up visit (Day 30)
Reported as:
Number · Percentage
Percentage of Participants With at Least One Treatment Emergent Adverse Event After Treatment
PercentageNaproxen Topical GelDiclofenac Diethylamine Topical GelPlacebo
any AE03.330
serious AE000
SecondaryNumber of Participants With at Least One Treatment Emergent Adverse Event After Treatment

An AE is any untoward medical occurrence in a clinical study participant, associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
After first treatment on Day 1 until follow-up visit (Day 30)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment Emergent Adverse Event After Treatment
ParticipantsNaproxen Topical GelDiclofenac Diethylamine Topical GelPlacebo
Rhinitis010
Nasal congestion010
Paranasal sinus hypersecretion010

Adverse events

Collected over Adverse event data were collected after first treatment on Day 1 until follow-up visit (Day 30).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naproxen Gel0/31 (0%)0/31 (0%)0/31 (0%)
Diclofenac Gel0/30 (0%)0/30 (0%)1/30 (3.3%)
Placebo Gel0/15 (0%)0/15 (0%)0/15 (0%)
Most frequent other events
Most frequent other events
EventNaproxen GelDiclofenac GelPlacebo Gel
RhinitisInfections and infestations0/311/300/15
Nasal congestionRespiratory, thoracic and mediastinal disorders0/311/300/15
Paranasal sinus hypersecretRespiratory, thoracic and mediastinal disorders0/311/300/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Naproxen Topical GelDiclofenac Diethylamine Topical GelPlaceboTotal
Mean33.32 ± 10.7431.57 ± 9.4732.47 ± 13.0532.46 ± 10.64
Sex: Female, Male
Sex: Female, Male(Participants)Naproxen Topical GelDiclofenac Diethylamine Topical GelPlaceboTotal
Female1616941
Male1514635
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Naproxen Topical GelDiclofenac Diethylamine Topical GelPlaceboTotal
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White29301574
More than one race0000
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Naproxen Topical GelDiclofenac Diethylamine Topical GelPlaceboTotal
Non-Hispanic/Latino21191050
Other911525
Unknown1001
08

Study locations

1 site
  • Deutsche Sporthochschule Köln (DSHS)
    Köln, Nordrhein-Westfalen 50933, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — There are no current plans to share data. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Dec 2021, 4 months.

Results were first posted in Jan 2025, 3 years 1 month after primary completion. A results delay was requested in Dec 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2021
First posted
Aug 30, 2021
StartActual
Aug 8, 2021
Primary completionActual
Dec 20, 2021
CompletionActual
Dec 20, 2021
Results delay requested
Dec 9, 2022
Results first posted
Jan 22, 2025
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05026320
Lead sponsor
Bayer
Collaborators
Deutsche Sporthochschule Köln
Responsible party
Sponsor
First posted
Aug 30, 2021
Start date
Aug 8, 2021
Primary completion
Dec 20, 2021
Completion
Dec 20, 2021
Results posted
Jan 22, 2025
Last update
Jan 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion